8-K: IO Biotech Secures €12.5 Million Tranche B Loan from EIB, Issues Warrants

IO Biotech, Inc. has announced the drawdown of a €12.5 million second tranche from its European Investment Bank loan facility, accompanied by the issuance of warrants for over 4.2 million common shares.

Summary

• IO Biotech, Inc. (the Company) has satisfied the conditions to draw €12.5 million in the second tranche (Tranche B) of its term loan facility with the European Investment Bank (EIB).
• This drawdown is part of a larger Finance Contract entered into on December 19, 2024, which established up to €57.5 million in potential financing across three committed and one uncommitted tranches.
• In connection with the Tranche B drawdown, on June 24, 2025, the Company issued to EIB a Tranche B warrant to purchase up to 4,221,867.59 shares of the Company's common stock.
• The strike price per share for the Tranche B warrant is $1.3159.
• The Company expects to draw down upon the Tranche B loan on or around July 4, 2025.
• The securities issued under this transaction were not registered under the Securities Act of 1933, with the Company relying on the exemption provided by Section 4(a)(2) for private offerings.
• The warrant has an initial exercise date of June 24, 2025, and a termination date of the earlier of June 24, 2045, or one day prior to the closing of an Acquisition.
• The warrant includes a beneficial ownership limitation, initially set at 4.99% of outstanding common stock, which the Warrantholder can increase up to 19.99% with notice to the Company.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Securing additional financing is a crucial positive for a biotech company, providing necessary capital. However, the issuance of warrants introduces potential future dilution, which is a neutral to slightly negative factor for existing shareholders, balancing the overall sentiment.

Positives

• The Company has successfully secured an additional €12.5 million in financing, enhancing its liquidity and financial runway.
• This drawdown is a progression of a previously established €57.5 million financing facility with the EIB, indicating continued support from a significant financial institution.
• The financing provides capital for ongoing operations and strategic initiatives without immediate public equity dilution, as the warrant exercise is contingent on future events.

Negatives

• The issuance of warrants for 4,221,867.59 shares at a strike price of $1.3159 introduces potential future dilution for existing shareholders if the warrants are exercised.
• The strike price of $1.3159, while a contractual term, could be perceived as relatively low depending on the Company's current market valuation, potentially indicating a discount for the financing.

Risks

• Future dilution of existing shareholders if the Tranche B warrant is exercised, increasing the number of outstanding common shares.
• The Company's ability to meet the conditions and obligations under the Finance Contract and the Tranche B Warrant.
• Market conditions and the Company's stock performance will influence the value and likelihood of the warrant's exercise.
• Restrictions on warrant exercise, such as the beneficial ownership limitation and the requirement for stockholder approval under Nasdaq rules, could impact the EIB's ability to fully exercise its warrant.

Future Outlook

The Company expects to complete the drawdown of the €12.5 million Tranche B loan on or around July 4, 2025, which will provide additional capital for its operations. The warrant issued in connection with this financing has a long-term exercise period, extending to June 2045, or earlier upon an acquisition.

Industry Context

This financing event is typical for a biotechnology company like IO Biotech, which often relies on external funding to support its research, development, and clinical trial activities. Securing non-dilutive (loan) and potentially dilutive (warrant) financing from institutions like the European Investment Bank is a common strategy to extend operational runway and advance pipeline assets in the capital-intensive biotech sector.

Comparison to Industry Standards

• The structure of a term loan combined with warrants is a common financing mechanism for biotech companies, allowing lenders to participate in potential upside while providing capital.
• The European Investment Bank (EIB) is a significant lender to innovative companies, particularly in the EU, and its involvement suggests a level of due diligence and confidence in IO Biotech's potential, similar to other biotech firms that secure funding from specialized life sciences debt providers or venture debt funds.
• The beneficial ownership limitation (4.99% initially, up to 19.99%) is a standard provision in warrants issued by publicly traded companies to avoid triggering certain regulatory thresholds or shareholder approval requirements (e.g., Nasdaq rules) without prior notice or vote.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential future dilution due to the exercise of the Tranche B warrant, which could increase the number of outstanding shares. However, the financing improves the Company's financial stability, which is beneficial.
• **Creditors (EIB)**: The EIB benefits from the loan interest and the potential upside from the warrant exercise, providing a structured return on their investment.
• **Employees**: Improved financial stability may provide greater job security and resources for ongoing projects.
• **Company Operations**: The additional capital provides funding for research, development, and general corporate purposes, supporting the Company's strategic objectives.

Next Steps

• The Company expects to draw down the €12.5 million Tranche B loan on or around July 4, 2025.
• The European Investment Bank may exercise its Tranche B warrant to purchase common stock shares at the specified strike price, subject to terms and limitations, until June 24, 2045, or earlier upon an acquisition.

Key Dates

Keywords

IO Biotech, EIB, European Investment Bank, Tranche B, Loan Facility, Warrant Issuance, Equity Securities, Financing, Debt, Biotechnology, SEC Filing, 8-K, Common Stock, Dilution, Capital Raise